Prostate Cryoablation Combined With Metronomic Cyclophosphamide for Metastatic Prostate Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this clinical trial is to explore whether androgen deprivation therapy combined with novel androgen receptor inhibitors, prostate cryoablation, and metronomic cyclophosphamide is superior to the current treatment regimen of androgen deprivation therapy plus novel androgen receptor inhibitors for patients with metastatic prostate cancer. It will also learn about the safety of prostate cryoablation, and metronomic cyclophosphamide for patients with metastatic prostate cancer. The main questions it aims to answer are: Does prostate cryoablation, and metronomic cyclophosphamide delay the progression of metastatic prostate cancer? Does prostate cryoablation, and metronomic cyclophosphamide reduce symptomatic local events of metastatic prostate cancer? Researchers will explore if androgen deprivation therapy combined with novel androgen receptor inhibitors, prostate cryoablation, and metronomic cyclophosphamide works to treat metastatic prostate cancer. Participants will: Receive treatment of androgen deprivation therapy and novel androgen receptor inhibitors until progression. Receive prostate cryoablation surgery and take cyclophosphamide. Visit the clinic every 1-3 months for checkups and tests. Keep a diary of their symptoms.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Mężczyźni w wieku 18-80 lat
- •Potwierdzony histologicznie rak gruczołu krokowego
- •Rak prostaty z przerzutami rozpoznany przy pierwszej diagnozie
- •Brak pogorszenia stanu przed planowanym zabiegiem zamrażania prostaty
- •Ogólny stan zdrowia pozwalający na uczestnictwo w badaniu (wynik ECOG 0-1)
- •Zdolność do tolerowania znieczulenia ogólnego i zabiegu zamrażania prostaty
- •Umiejętność zrozumienia badania i podpisania zgody
✗ Disqualifies
- •Poważne choroby uniemożliwiające uczestnictwo w leczeniu
- •Inne nowotwory w ciągu ostatnich 5 lat (poza rakiem skóry)
- •Wcześniejsze leczenie innymi metodami niż przewidziane w badaniu
- •Rak prostaty naciekający odbytnicę
- •Prostata powiększona ponad 55ml po 6 miesiącach terapii hormonalnej
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 80 Years
- Last updated (source)
- August 28, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (1)
Sun Yat-sen University Cancer Center
Guangzhou, China
Trial contact
Zhenyu Yang, Dr.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/29/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.